1. Home
  2. GNS vs XLO Comparison

GNS vs XLO Comparison

Compare GNS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genius Group Limited

GNS

Genius Group Limited

HOLD

Current Price

$0.23

Market Cap

54.7M

Sector

Real Estate

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.79

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNS
XLO
Founded
2002
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.7M
49.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
GNS
XLO
Price
$0.23
$8.79
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
14.3M
22.6K
Earning Date
03-09-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
$156.26
N/A
Revenue Next Year
$35.38
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$0.20
$0.46
52 Week High
$1.92
$9.25

Technical Indicators

Market Signals
Indicator
GNS
XLO
Relative Strength Index (RSI) 43.30 61.52
Support Level $0.21 $7.47
Resistance Level $0.48 $8.97
Average True Range (ATR) 0.03 0.42
MACD -0.00 0.03
Stochastic Oscillator 26.93 95.63

Price Performance

Historical Comparison
GNS
XLO

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: